Confirmed Conference Exhibitors

Action for Pulmonary Fibrosis (APF) is a growing community of patients, families, researchers and healthcare professionals striving to find a cure for pulmonary fibrosis so that everyone affected by the disease has a better future. We provide personalised support to patients and families – and raise awareness of pulmonary fibrosis through campaigning, fundraising and education. We are also committed to funding research to improve quality of life for people living with pulmonary fibrosis today and tomorrow.

The origins of Alturix can be traced back to 1998 and the acquisition of three branded products which have been reliably supplied to the NHS for over twenty years. We are now a small but fast growing, dynamic pharmaceutical company who are committed to building and nurturing meaningful partnerships with our customers in the UK, and internationally. We are dedicated to delivering a growing portfolio of high quality products to help improve patient outcomes, at responsible prices. This is in accordance with our values of Integrity, Partnership and Reliability.

Established in 2009, Aspire is a privately owned British company offering a range of medicines, medical devices, diagnostics and OTC products. Each product is carefully thought through, offering value and differentiation to patients and healthcare professionals.

The Association of Respiratory Nurse Specialists (ARNS) was established in 1997 as a nursing forum to champion the specialty respiratory nursing community, promote excellence in practice, and influence respiratory health policy. ARNS also works to influence the direction of respiratory nursing care. ARNS has built its reputation in the following ways:
Respiratory Nurse Leadership
Evidence Based Practice
Discussion and Networking
Collaboration with the Nursing Times
Empowering

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The company concentrates on developing innovative therapies that can improve patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

BTS has 3,700 members in the UK, from all areas of respiratory health care. Our objectives are to improve the standards of care for people who have lung diseases; to raise awareness of the causes and prevention of lung disease; and to advocate for improved systems for delivery of services and support for the workforce. We believe that development of effective integrated respiratory services are the way forward. Our Respiratory Futures prrogramme provides a platform for resources to support integrated respiratory care, commissioning, innovation and networking. It works to join the dots between the many points, people and places that make up the diverse UK respiratory sector. This is with the aim of fostering the sharing of best practice, the reduction of duplication and the development of new models of care which best meet the needs of patients and help to reduce healthcare inequalities. Respiratory Futures works in partnership with NHS England to support the NHSE Long Term Plan’s ambitions for respiratory services.

In addition to an active website, Respiratory Futures holds live debates to promote discussion and learning in the respiratory community.

Chiesi Limited is the UK affiliate of Chiesi Farmaceutici S.p.A. It is headquartered in Manchester and employs over 250 employees. Chiesi Farmaceutici is an international research-focussed Healthcare Group based in Parma, Italy, with over 80 years of experience in the pharmaceutical industry. The group employs nearly 5,000 people and has affiliates in 26 countries. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare disease areas. Its R&D organisation is also headquartered in Parma, Italy, and integrated with six other key R&D groups in France, the USA, the UK, Sweden and Denmark to advance Chiesi's pre-clinical, clinical and registration programmes. .

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of patients. Since forming over 80 years ago, Cipla has emerged as one of the most respected pharmaceutical names in India and has a presence in more than 80 countries.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001.
Cipla is the world’s second largest suppliers of inhaled respiratory products and is now introducing its range of respiratory brands into the UK.

Circassia is the leading provider of point of care FeNO (Fractional exhaled Nitric Oxide) testing. Our market-leading NIOX® products are used by specialists throughout the UK and around the world to support confident diagnosis and management of asthma. NIOX VERO® measures FeNO quickly and accurately assesses the airway inflammation. As a result, NIOX® is used to improve asthma management by assisting in diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, reducing exacerbations and monitoring treatment compliance. For more information, please visit www.niox.com or get in touch at info@circassia.com.

GSK is a science-led global healthcare company with a mission to help people do more, feel better and live longer. For more than 50 years, GSK has been a leader in respiratory, helping patients with respiratory disease better manage their condition. Working in collaboration with the scientific community, we remain at the cutting-edge of scientific research into innovative medicines with the aim of helping to treat patients’ symptoms and reduce the risk of their disease.
For further information please visit www.gsk.com.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical
organization with operations in more than 80 countries. It is ranked among the top
75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100
Rankings published in the year 2018). Glenmark is a leading player in the discovery
of new molecules both NCEs (new chemical entity) and NBEs (new biological
entity). Glenmark has several molecules in various stages of clinical development
and is focused in the areas of respiratory, oncology, immunology and pain.

Around 1 in 3 inpatients and 1 in 5 outpatients with Chronic Obstructive Pulmonary Disease (COPD) are at risk of malnutrition. The causes are varied and include not only the physiological effects of the disease such as breathlessness and fatigue interfering with appetite and the ability to eat but also psychological, social and environmental factors such as depression, social isolation and living conditions. In addition, individuals with COPD may have increased energy requirements arising from systemic inflammation and increased effort associated with breathing. Malnutrition can develop over several years or be precipitated and continue following an acute exacerbation.

The ‘Managing Malnutrition in COPD’ (www.malnutritionpathway.co.uk/copd ) and ‘Managing Adult Malnutrition in the Community’ (www.malnutritionpathway.co.uk ) guides and patient materials aim to raise awareness of the issue of disease-related malnutrition in the community and provide professionals and patients with materials to assist them to identify, manage and reverse malnutrition. The materials have been developed by a multi-professional panel and are based on clinical evidence, clinical experience and best practice and are endorsed by key professional and patient associations.

npj Primary Care Respiratory Medicine is an open access journal published in partnership between Primary Care Respiratory Society and Springer Nature. The journal is dedicated to publishing high-quality research in all areas of the primary care management of respiratory and respiratory-related allergic diseases. Find out more: nature.com/npjpcrm

SpiroConnect is a PC based Bluetooth spirometer. It has a patented vertically orientated turbine which is more sensitive to low flow rates than horizontal turbine designs, resulting in more accurate spirometry measurements. SpiroConnect is the perfect spirometry solution for IN-CAR TESTING, SPIROMETRY HUBS and POST COVID CLINICS during the COVID-19 pandemic for the following reasons:

• BLUETOOTH CONNECTIVITY – works through glass and plastic safety screens at a range of up to 20 metres.
• VIRAL/BACTERIAL FILTERS - Numed filters give 99.99% viral/bacterial filtration at a flow rate of 750 litres/min.
• QUICK AND EASY DISINFECTION of the turbine can be performed between patients in a solution of PeraSafe.
• MULTIPLE TURBINES can be used in rotation with a single SpiroConnect device if required.
• ANTI-VIRAL/BACTERIAL WIPES can be used to quickly disinfect the body of the spirometer.
• LOW COST RENTAL OPTIONS are available, starting from £39 + VAT/month.
• FULLY INTEGRATED with SystmOne, EMIS and Vision clinical systems for faster, safer and easier testing.

For more information contact Numed Healthcare
Website: www.numed.co.uk
Email: info@numed.co.uk
Telephone: 0114 2433896

Orion Pharma (UK) Ltd. is a subsidiary of Orion Corporation, a pharmaceutical company based in Finland. Orion carries out extensive research with a goal of introducing new treatments into global markets. Core therapy areas in Orion’s product and research strategy are Respiratory, Critical Care, CNS, Women’s Health and oncology.

The aim of the Pulmonary Fibrosis Trust is to provide personal support to people affected by Pulmonary Fibrosis, a very debilitating and life-limiting illness.

We offer practical, emotional and financial support where there is a need. We also raise awareness of the illness and in particular the challenges people face on a daily basis.

Sanofi Genzyme is a business unit of Sanofi Group providing hope to people with high unmet needs including respiratory diseases, atopic dermatitis, rheumatoid arthritis, multiple sclerosis and ultra-rare diseases.

We are delighted to be supporting the Primary Care Respiratory Society Annual Conference to help promote the role that digital technology can take in improving the lives of patients with respiratory diseases.

We strive to promote best practice in respiratory care through our work in remote monitoring for COPD patients and Pulmonary Rehabilitation services, and our initiative with the European Space Agency on providing vulnerable patients with access to satellite-based air quality information.

CliniTouch Vie is our proven virtual clinical solution which provides monitoring, enables chronic disease management and delivers targeted education to patients, within a mobile device at home.

How it helps:
• Vital signs monitoring - uses any Bluetooth device for accurate clinical measurements.
• Health question sets - tailored to each patient's medical conditions.
• Patient education - empowers patients in self-care and wellbeing.
• Risk calculation - sophisticated algorithms assess the health risks for each patient.
• Messaging - sends messages to patients and ask them questions.
• Video calls - simple video consultations
• Prioritised caseloads - patient lists are displayed with red, amber or green status.
• Health trends - monitor how a patient's health changes over time.

To find out more, visit www.spirit-digital.co.uk or email us at info@spirit-digital.co.uk

Vitalograph is a global leader in respiratory solutions. We manufacture and supply high-quality spirometers and medical devices which aid the detection, diagnosis and management of respiratory conditions. We serve global markets from our operations in UK, Ireland, Germany, USA, Japan and China. Our products are chosen and used by medical professionals in over 113 countries worldwide.

We have been in business for over half a century because we care about providing quality products and data you can trust. Vitalograph devices are quick and easy to use, and new products are being added to the range.

Visit our stand to view our fast and accurate lung & asthma monitors, COPD screeners and inhaler trainers. Our spirometers are available in PC-based, desktop and handheld versions, and are durable and reliable with low running costs. View our spirometry and reporting software, which is designed to allow connectivity to practice software. We have a broad range of consumables including Bacterial Viral Filters which reduce the need for device cleaning by providing protection for patients, medical personnel and equipment.

Our focus is always on improving patient lives and patient outcomes through our accurate, high-quality devices and services.

We pride ourselves on excellence and innovation.